STCube, Inc. (KOSDAQ:052020)

Market Cap	497.95B
Revenue (ttm)	6.81B
Net Income (ttm)	-20.15B
Shares Out	67.93M
EPS (ttm)	-310.38
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	230,432
Average Volume	253,561
Open	7,310.00
Previous Close	7,420.00
Day's Range	7,160.00 - 7,490.00
52-Week Range	3,940.00 - 10,470.00
Beta	0.09
RSI	44.44
Earnings Date	Mar 17, 2026

About STCube

STCube, Inc., a biopharmaceutical company, develops medicines in South Korea. The company develops anti-cancer immunotherapeutic drugs and anti-viral drugs. It offers platform technologies, which include In vivo RNAi ICP target discovery platform for exploring material ICP target; glycosylation-specific antibody development platform for development of antibodies that mask glycosylation sites on target proteins; and ICP functional assay platform for development of various in vivo/in vitro analytical/experimental methods. The company’s product pi...

• Industry: Electronic Parts and Equipment, not elsewhere classified
• Founded: 1989
• Employees: 13
• Stock Exchange: KOSDAQ
• Ticker Symbol: 052020

Financial Performance

In 2024, STCube's revenue was 11.30 billion, an increase of 93.88% compared to the previous year's 5.83 billion. Losses were -21.44 billion, -12.52% less than in 2023.